Related Experiment Video
Updated: Jun 6, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami1,2,3, Kristen E Pauken2, Linghua Wang3,4,5
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Immune checkpoint therapy has revolutionized cancer treatment, leading to dramatic clinical outcomes for a subset of patients. However, many patients do not experience durable responses following immune checkpoint therapy owing to multiple resistance mechanisms, highlighting the need for effective combination strategies that target these resistance pathways and improve clinical responses. The development of combination strategies based on an understanding of the complex biology that regulates human antitumor immune responses has been a major challenge. In this Review, we describe the current landscape of combination therapies. We also discuss how the development of effective combination strategies will require the integration of small, tissue-rich clinical trials, to determine how therapy-driven perturbation of the human immune system affects downstream biological responses and eventual clinical outcomes, reverse translation of clinical observations to immunocompetent preclinical models, to interrogate specific biological pathways and their impact on antitumor immune responses, and novel computational methods and machine learning, to integrate multiple datasets across clinical and preclinical studies for the identification of the most relevant pathways that need to be targeted for successful combination strategies.
Insights
Immune checkpoint therapy shows promise but faces resistance. Effective combination strategies require integrating clinical trials, preclinical models, and computational methods to overcome resistance and improve cancer treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immune checkpoint therapy has transformed cancer treatment for some patients.
- Many patients do not achieve lasting responses due to resistance mechanisms.
- Developing effective combination strategies is crucial to improve clinical outcomes.
Purpose of the Study:
- To review the current landscape of cancer therapy combinations.
- To discuss the challenges and requirements for developing effective combination strategies.
- To highlight the need for integrated approaches to understand and overcome resistance.
Main Methods:
- Review of existing literature on immune checkpoint therapy and combination strategies.
- Discussion of integrating clinical trials, preclinical models, and computational methods.
- Emphasis on reverse translation from clinical observations to preclinical models.
Main Results:
- Immune checkpoint therapy offers significant benefits but is limited by resistance.
- Combination strategies are essential for enhancing durable responses.
- Understanding tumor immune response biology is key to developing successful combinations.
Conclusions:
- Effective combination strategies necessitate integrating clinical, preclinical, and computational approaches.
- Targeting resistance pathways requires a multi-faceted research strategy.
- Future advancements depend on a holistic understanding of immune system modulation in cancer.
More Related Videos
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...